ARYL OR HETEROARYL DERIVATIVE

WIPO Patent Application WO/2021/210650

A1

A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1–X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.)

WO/2002/076926	3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS
WO/2017/038873	UREA DERIVATIVE AND USE THEREFOR

SUGIYAMA SAKAE (JP)
YOKOSAKA TAKUYA (JP)
MINAMIZONO KUNIO (JP)
KAWANA ASAHI (JP)
KANEKO TOSHIYUKI (JP)
MARUYAMA AKINOBU (JP)
SASAKI KOSUKE (JP)
HOSODA SHINNOSUKE (JP)
KOSHIMIZU MASAKI (JP)
TAKEUCHI SUSUMU (JP)
KATO KENTA (JP)
CHAKKA NAGASREE (US)
JOHNSON BRETT M (US)
WHITE RYAN D (US)
ZHAO WEI (US)

PCT/JP2021/015607

October 21, 2021

April 15, 2021

Click for automatic bibliography generation  

TEIJIN PHARMA LTD (JP)
AMGEN INC (US)

C07D213/74; A61K31/427; A61K31/4439; A61K31/444; A61K31/501; A61K31/506; A61K31/5377; A61K31/551; A61P3/10; A61P7/10; A61P9/04; A61P9/12; A61P11/00; A61P13/12; A61P21/04; A61P31/04; A61P35/00; A61P43/00; C07D237/20; C07D239/34; C07D239/42; C07D239/47; C07D239/48; C07D239/52; C07D401/10; C07D401/12; C07D401/14; C07D403/10; C07D403/12; C07D403/14; C07D417/04; C07D417/10; C07D417/12; C07D487/08

WO2013045519A1	2013-04-04
WO2019081637A1	2019-05-02
WO2011107474A1	2011-09-09
WO2014192865A1	2014-12-04
WO2019208812A1	2019-10-31
WO2012037351A1	2012-03-22
WO2019079578A1	2019-04-25

US4315926A	1982-02-16
CN104292233A	2015-01-21
CN106317050A	2017-01-11
CN107253952A	2017-10-17

ZHANG,L. ET AL.: "Experimental and Theoretical Studies on Ru(II)-Catalyzed Oxidative C-H/C-H Coupling of Phenols with Aromatic Amides Using Air as Oxidant: Scope, Synthetic Applications, and Mechanistic Insights", ACS CATALYSIS, vol. 8, no. 9, 2018, pages 8324 - 8335, XP055867445, DOI: 10.1021/acscatal.8b02816
MARINHO,E. ET AL.: "The reaction of anthranilonitrile and triethylorthoformate revisited: formation of dimeric and trimeric species", TETRAHEDRON, vol. 66, no. 45, 2010, pages 8681 - 8689, XP027415294, DOI: 10.1016/ j.tet. 2010.09.01 3
J. CLIN. INVEST., vol. 116, 2006, pages 3114 - 3126
DEV. CELL., vol. 23, 2012, pages 705 - 715
CIRC. RES., vol. 114, 2014, pages 823 - 832
PROC. NATL. ACD. SCI. USA, vol. 103, 2006, pages 19093 - 19098
J. CARDIOVASC. PHARMACOL., vol. 57, 2011, pages 140 - 147
HYPERTENSION, vol. 63, 2014, pages 173 - 80
CLIN. EXP. ALLERGY, vol. 38, 2008, pages 1548 - 1558
ACTA. PHYSIOL., vol. 195, 2009, pages 3 - 11
J. EXP. MED., vol. 209, 2011, pages 1953 - 1968
ARTERIOSCLER. THROMB. VASE. BIOL., vol. 33, 2013, pages 2121 - 2129
PLOS ONE, vol. 5, 2010, pages e12859
EXPERT. OPIN. THER. TARGETS., vol. 14, 2010, pages 513 - 27
BMC CANCER, vol. 13, 2013, pages 116
SCIENCE, vol. 308, 2005, pages 1801 - 1804
NAT. GENET., vol. 37, 2005, pages 739 - 744
PLOS ONE, vol. 4, 2009, pages e7771
CLIN. J. AM. SOC. NEPHROL., vol. 6, 2011, pages 1139 - 1148
MOL. BIOL. CELL., vol. 22, 2011, pages 1824 - 1835
BMC NEPHROL, vol. 14, 2013, pages 104
PEDIATR. RES., vol. 74, 2013, pages 511 - 516
NEPHROL. DIAL. TRANSPLANT., vol. 28, 2013, pages 1830 - 1838
CIRCULATION, vol. 119, 2009, pages 2313 - 2322
J. AM. SOC. NEPHROL., vol. 18, 2007, pages 29 - 36
MOL IMMUNOL. FEB, vol. 94, 2018, pages 75 - 81
"PROTECTIVE GROUPS in ORGANIC SYNTHESIS", JOHN WILEY&SONS, INC
See also references of EP 4137481A4

AOKI, Atsushi et al. (JP)

View/Download PDF      PDF Help

Previous Patent: CYLINDER HEAD, CYLINDER BLOCK, INTERNAL COMBUSTION ENGINE, AND METHOD FOR MANUFACTURING CYLINDER HEA...

Next Patent: PROTEIN DIAGNOSTIC BIOMARKER FOR SEVERE DRUG ERUPTION